医学
结直肠癌
内科学
放化疗
肿瘤科
新辅助治疗
癌症
乳腺癌
作者
Susan G. R. McDuff,Karin M. Hardiman,Peter Ulintz,Aparna R. Parikh,Hui Zheng,Daniel W. Kim,Jochen K. Lennerz,Mehlika Hazar-Rethinam,Emily E. Van Seventer,Isobel J. Fetter,Brandon Nadres,Christine E. Eyler,David P. Ryan,Colin D. Weekes,Jeffrey W. Clark,James C. Cusack,Lipika Goyal,Andrew X. Zhu,Jennifer Y. Wo,Lawrence S. Blaszkowsky
摘要
Among patients treated with neoadjuvant chemoradiation for LARC, patients with undetectable preoperative ctDNA were more likely to have a favorable surgical outcome as measured by the rate of margin-negative, node-negative resections and neoadjuvant rectal score. Furthermore, we have confirmed prior reports indicating that detectable postoperative ctDNA is associated with worse RFS. Future prospective study is needed to assess the potential for ctDNA to assist with personalizing treatment for LARC.
科研通智能强力驱动
Strongly Powered by AbleSci AI